{"id":"abatacept-plus","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infection (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL1201823","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept (CTLA4-Ig) acts as a selective costimulation modulator that interrupts the second signal required for full T-cell activation. By binding to CD80 and CD86 molecules on dendritic cells and other antigen-presenting cells, it prevents interaction with CD28 on T cells, reducing inflammatory cytokine production and T-cell proliferation. This mechanism makes it effective in autoimmune and inflammatory conditions where T-cell dysregulation is central to pathogenesis.","oneSentence":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:29.549Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Systemic lupus erythematosus (Phase 3)"}]},"trialDetails":[{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT02840175","phase":"PHASE3","title":"Treatment Tapering in JIA With Inactive Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06918990","phase":"PHASE2","title":"Treatment of Antibody-Mediated Rejection (ABMR) With CarBel","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-15","conditions":"Kidney Transplant Rejection","enrollment":25},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT03924401","phase":"PHASE2","title":"Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-08-22","conditions":"Graft Versus Host Disease","enrollment":30},{"nctId":"NCT05017545","phase":"PHASE1, PHASE2","title":"Carfilzomib and Belatacept for Desensitization","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-28","conditions":"Highly Sensitized Prospective Kidney Transplant Recipients","enrollment":21},{"nctId":"NCT04380740","phase":"PHASE2","title":"Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2022-03-30","conditions":"Graft Vs Host Disease","enrollment":160},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT07366801","phase":"PHASE2, PHASE3","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-09-03","conditions":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk","enrollment":64},{"nctId":"NCT03841357","phase":"PHASE3","title":"Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-10-29","conditions":"Juvenile Idiopathic Arthritis","enrollment":121},{"nctId":"NCT04827979","phase":"PHASE1, PHASE2","title":"Daratumumab and Belatacept for Desensitization","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Highly Sensitized Prospective Kidney Transplant Recipients","enrollment":19},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT06731504","phase":"EARLY_PHASE1","title":"HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-12","conditions":"Hematologic Malignancy","enrollment":10},{"nctId":"NCT05669001","phase":"PHASE2","title":"A Study of TCD601 in de Novo Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2023-12-28","conditions":"Renal Transplantation","enrollment":76},{"nctId":"NCT04786067","phase":"PHASE4","title":"Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-07-28","conditions":"Kidney Transplant Immunosuppression","enrollment":25},{"nctId":"NCT06008808","phase":"PHASE1","title":"Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-07","conditions":"Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease","enrollment":41},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT05742243","phase":"PHASE2","title":"Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2023-02-13","conditions":"Type 1 Diabetes, Diabetes Mellitus, Type 1","enrollment":68},{"nctId":"NCT06145282","phase":"PHASE1, PHASE2","title":"Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2023-12-28","conditions":"Sickle Cell Disease","enrollment":6},{"nctId":"NCT01743131","phase":"PHASE2","title":"Abatacept as GVHD Prophylaxis Phase 2","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-02-01","conditions":"Graft vs Host Disease, Malignancy","enrollment":186},{"nctId":"NCT05345717","phase":"PHASE1, PHASE2","title":"Novel Desensitization Kidney Transplantation","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2022-05-01","conditions":"Kidney Transplantation, End Stage Kidney Disease (ESRD)","enrollment":5},{"nctId":"NCT05421442","phase":"","title":"A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-06-13","conditions":"Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)","enrollment":38396},{"nctId":"NCT05413044","phase":"","title":"A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-07-01","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":140706},{"nctId":"NCT04477629","phase":"PHASE2","title":"Belatacept in De Novo Heart Transplantation","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2020-08-06","conditions":"Heart Transplantation","enrollment":12},{"nctId":"NCT07238712","phase":"PHASE2","title":"Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2025-05-10","conditions":"Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","enrollment":60},{"nctId":"NCT04925375","phase":"PHASE2","title":"Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-07-14","conditions":"Interstitial Lung Disease, Common Variable Immunodeficiency","enrollment":38},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT03680092","phase":"PHASE2","title":"Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation","status":"COMPLETED","sponsor":"Dimitrios Tzachanis, MD PhD","startDate":"2019-11-26","conditions":"GVHD, Hematologic Neoplasms","enrollment":43},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT01357668","phase":"","title":"An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2013-01-30","conditions":"Juvenile Idiopathic Arthritis","enrollment":800},{"nctId":"NCT05335928","phase":"PHASE3","title":"Abatacept in Immune Checkpoint Inhibitor Myocarditis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-07-02","conditions":"Myocarditis Acute, Cancer","enrollment":390},{"nctId":"NCT05822583","phase":"PHASE4","title":"Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-07-06","conditions":"COVID-19","enrollment":285},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT05708534","phase":"","title":"Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2023-11-14","conditions":"Kidney Transplant Infection","enrollment":28},{"nctId":"NCT02758769","phase":"","title":"Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-06-07","conditions":"Rheumatoid Arthritis","enrollment":303},{"nctId":"NCT06680661","phase":"PHASE2","title":"ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2025-02-25","conditions":"Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia","enrollment":20},{"nctId":"NCT06929039","phase":"PHASE1","title":"Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2024-07-04","conditions":"Rheumatoid Arthritis (RA","enrollment":300},{"nctId":"NCT04736381","phase":"","title":"Impact of the Microbiota on the Likelihood of Renal Graft Rejection","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2021-10-07","conditions":"Kidney Transplant Rejection","enrollment":70},{"nctId":"NCT02310867","phase":"PHASE2","title":"Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy","status":"RECRUITING","sponsor":"Linda Cendales","startDate":"2015-03","conditions":"Immunosuppression","enrollment":50},{"nctId":"NCT01247766","phase":"","title":"Safety Study of Abatacept to Treat Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12-31","conditions":"Rheumatoid Arthritis","enrollment":6367},{"nctId":"NCT05975450","phase":"PHASE1","title":"Subcutaneous Abatacept in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Idelberto Badell","startDate":"2023-08-02","conditions":"Kidney Transplant Recipient","enrollment":14},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT06395038","phase":"PHASE1","title":"IL-2 Plus Abatacept in FTD","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-05-06","conditions":"Frontotemporal Degeneration","enrollment":10},{"nctId":"NCT03457142","phase":"PHASE2","title":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-09-11","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":15},{"nctId":"NCT03669367","phase":"PHASE4","title":"EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2019-06-03","conditions":"Palindromic Rheumatism, Wrist","enrollment":70},{"nctId":"NCT04909801","phase":"PHASE3","title":"A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-09-15","conditions":"Rheumatoid Arthritis","enrollment":338},{"nctId":"NCT03215927","phase":"PHASE2","title":"Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease","status":"COMPLETED","sponsor":"Rohit Aggarwal, MD","startDate":"2018-01-01","conditions":"Myositis, Interstitial Lung Disease","enrollment":20},{"nctId":"NCT06756152","phase":"PHASE2, PHASE3","title":"Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2024-07-10","conditions":"Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, Myeloblastic Leukemia","enrollment":50},{"nctId":"NCT04046549","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-10-30","conditions":"Allografts, Rejection; Transplant, Kidney, Transplant Rejection","enrollment":25},{"nctId":"NCT05289167","phase":"PHASE1, PHASE2","title":"Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwell Health","startDate":"2022-03-13","conditions":"Graft-versus-host Disease","enrollment":74},{"nctId":"NCT05195645","phase":"PHASE2","title":"AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-10-04","conditions":"Myocarditis","enrollment":21},{"nctId":"NCT04872218","phase":"PHASE2","title":"Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy","status":"COMPLETED","sponsor":"Philippe Bégin","startDate":"2022-03-01","conditions":"Peanut Allergy","enrollment":14},{"nctId":"NCT03737708","phase":"PHASE4","title":"A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2019-02-13","conditions":"Rheumatoid Arthritis (RA)","enrollment":21},{"nctId":"NCT04503616","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-09-16","conditions":"Graft-versus-host Disease","enrollment":46},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT06475820","phase":"PHASE2, PHASE3","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2023-12-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia","enrollment":150},{"nctId":"NCT03882008","phase":"PHASE4","title":"A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-05-23","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02108860","phase":"PHASE3","title":"Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2015-04-25","conditions":"Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis","enrollment":65},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":10000},{"nctId":"NCT06307301","phase":"PHASE1","title":"Study in ALS With Abatacept & IL-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-10-28","conditions":"Amyotrophic Lateral Sclerosis","enrollment":5},{"nctId":"NCT01954979","phase":"PHASE1","title":"Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2014-03-27","conditions":"Chronic Graft Versus Host Disease","enrollment":56},{"nctId":"NCT04186871","phase":"PHASE2","title":"Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-07","conditions":"Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus","enrollment":119},{"nctId":"NCT05426252","phase":"PHASE1, PHASE2","title":"Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia","status":"RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2022-03-22","conditions":"Thalassemia in Children","enrollment":20},{"nctId":"NCT04177095","phase":"PHASE4","title":"Immune Monitoring to Facilitate Belatacept Monotherapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-02-11","conditions":"Kidney Transplant Rejection, Immunosuppression","enrollment":17},{"nctId":"NCT03733067","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-11-30","conditions":"CTLA4 Haploinsufficency, Chronic Cytopenia","enrollment":""},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":"Eye Diseases, Uveitis","enrollment":15},{"nctId":"NCT04251741","phase":"PHASE4","title":"Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment","status":"UNKNOWN","sponsor":"Reade Rheumatology Research Institute","startDate":"2020-07-31","conditions":"Rheumatoid Arthritis","enrollment":86},{"nctId":"NCT02971683","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-04","conditions":"Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy","enrollment":149},{"nctId":"NCT05515029","phase":"PHASE3","title":"Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-08-23","conditions":"Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia","enrollment":56},{"nctId":"NCT03227419","phase":"PHASE4","title":"Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders","status":"UNKNOWN","sponsor":"Lille Catholic University","startDate":"2018-01-22","conditions":"Arthritis, Rheumatoid","enrollment":224},{"nctId":"NCT01087125","phase":"","title":"Abatacept Pregnancy Exposure Registry","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-09-01","conditions":"Rheumatoid Arthritis","enrollment":42},{"nctId":"NCT01844518","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-30","conditions":"Active Polyarticular Juvenile Idiopathic Arthritis","enrollment":219},{"nctId":"NCT03188081","phase":"","title":"A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":171},{"nctId":"NCT04255134","phase":"PHASE4","title":"Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2020-09-07","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT02797769","phase":"","title":"A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-02","conditions":"Rheumatoid Arthritis","enrollment":48950},{"nctId":"NCT04686929","phase":"PHASE1, PHASE2","title":"Abatacept s.c. for aGVHD Prevention in Haplo-HCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-06-01","conditions":"Abatacept, Acute-graft-versus-host Disease, Haplo-identical HCT","enrollment":29},{"nctId":"NCT01953120","phase":"PHASE4","title":"Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2013-10","conditions":"Renal Transplant Rejection","enrollment":20},{"nctId":"NCT02939365","phase":"PHASE4","title":"Precision Medicine Offers Belatacept Monotherapy","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2019-02","conditions":"Transplantation","enrollment":""},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT04472494","phase":"PHASE2","title":"Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-10-14","conditions":"COVID-19, SARS-CoV-2","enrollment":61},{"nctId":"NCT05451615","phase":"PHASE3","title":"Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2022-09-30","conditions":"Abatacept, Treatment Compliance, Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT02594735","phase":"PHASE4","title":"Abatacept in Juvenile Dermatomyositis","status":"COMPLETED","sponsor":"George Washington University","startDate":"2015-11","conditions":"Dermatomyositis","enrollment":10},{"nctId":"NCT03492658","phase":"PHASE4","title":"Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2018-05-17","conditions":"Rheumatoid Arthritis, Rheumatic Diseases","enrollment":46},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03331393","phase":"","title":"The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-16","conditions":"Rheumatoid Arthritis","enrollment":265},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":183,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Orencia"],"phase":"phase_3","status":"active","brandName":"Abatacept plus","genericName":"Abatacept plus","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}